


REMARKS

The purpose of the forgoing Amendment is to submit the Abstract on a single separate sheet and to delete multiple dependent claims, placing the application in better form for examination under U.S. practice. No new matter is entered.

Respectfully submitted,



Thomas P. Pavelko

Registration No. 31,689

TPP/mat

Attorney Docket No.: TPP 31440

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.

1615 L Street, N.W., Suite 850

Washington, D.C. 20036

Telephone: (202) 785-0100

Facsimile: (202) 408-5200 or (202) 408-5088

Date: March 14, 2002

ATTACHMENT I

## ABSTRACT

The present invention relates to the IGS3 G-protein coupled receptor family, and to polynucleotides encoding said IGS3 proteins. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and non-human transgenic animals where the IGS3-gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS3 and the use of IGS3 polypeptides and polynucleotides and agonists or antagonists to the IGS3 receptor family in the treatment of a broad range of disorders and diagnostic assays for such conditions.

ATTACHMENT II

5. (Amended) The polynucleotide of claim 1[-4], which is DNA or RNA.
10. (Amended) IGS3 receptor membrane preparation derived from a cell according to claim 7[-9].